Over the last 12 months, Lexeo Therapeutics insiders reported no purchases and 14 sales totaling $722K across SEC Form 4 filings. 7% of those filings were made under pre-arranged 10b5-1 trading plans.
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Decision | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Tamayo Louis EdwardChief Financial Officer · O | ▼ Sale | Non-discretionarytax on vesting | 4,117 | $4.91 | $20K | -4.2% | — |
| Aug 18, 2026 | Townsend Richard NolanChief Executive Officer · O·D | ▼ Sale | Non-discretionarytax on vesting | 3,345 | $4.95 | $17K | -0.9% | — |
| Aug 18, 2026 | Otero Jose ManuelChief Operating Officer · O | ▼ Sale | Non-discretionarytax on vesting | 1,304 | $4.96 | $6K | -0.9% | — |
| Jul 1, 2026 | Tamayo Louis EdwardChief Financial Officer · O | ▼ Sale | Non-discretionarytax on vesting | 4,641 | $4.49 | $21K | -4.6% | — |
| Jul 1, 2026 | Otero Jose ManuelChief Operating Officer · O | ▼ Sale | Non-discretionarytax on vesting | 4,666 | $4.48 | $21K | -3.3% | — |
| Jul 1, 2026 | Bhalla Narinder PalChief Medical Officer · O | ▼ Sale | Non-discretionarytax on vesting | 22,306 | $4.42 | $99K | -21.3% | — |
| Jul 1, 2026 | Townsend Richard NolanChief Executive Officer · O·D | ▼ Sale | Non-discretionarytax on vesting | 25,947 | $4.48 | $116K | -6.4% | — |
| Apr 6, 2026 | Townsend Richard NolanChief Executive Officer · O·D | ▼ Sale | Non-discretionary10b5-1 plan | 55,000 | $5.69 | $313K | -13.9% | — |
| Feb 18, 2026 | Otero Jose ManuelChief Operating Officer · O | ▼ Sale | Non-discretionarytax on vesting | 3,016 | $6.4 | $19K | -2.3% | — |
| Feb 18, 2026 | Townsend Richard NolanChief Executive Officer · O·D | ▼ Sale | Non-discretionarytax on vesting | 10,173 | $6.38 | $65K | -2.5% | — |
| Nov 18, 2025 | See Tai SandiChief Development Officer · O | ▼ Sale | Non-discretionarytax on vesting | 386 | $9.27 | $4K | -0.6% | — |
| Nov 18, 2025 | Townsend Richard NolanChief Executive Officer · O·D | ▼ Sale | Non-discretionarytax on vesting | 1,127 | $9.27 | $10K | -0.5% | — |
| Nov 18, 2025 | Robertson JennyChief Legal Officer · O | ▼ Sale | Non-discretionarytax on vesting | 549 | $9.27 | $5K | -0.8% | — |
| Nov 18, 2025 | Adler EricChief Medical Officer · O | ▼ Sale | Non-discretionarytax on vesting | 615 | $9.27 | $6K | -0.8% | — |
| Oct 17, 2025 | Otero Jose ManuelChief Technical Officer · O | ▼ Sale | Non-discretionarytax on vesting | 2,115 | $8.94 | $19K | -3.2% | 2 tranches |
| Oct 17, 2025 | See Tai SandiChief Development Officer · O | ▼ Sale | Non-discretionarytax on vesting | 3,888 | $8.94 | $35K | -5.6% | 2 tranches |
| Oct 17, 2025 | Townsend Richard NolanChief Executive Officer · O·D | ▼ Sale | Non-discretionarytax on vesting | 13,133 | $8.94 | $117K | -5.1% | 2 tranches |
| Oct 17, 2025 | Robertson JennyChief Legal Officer · O | ▼ Sale | Non-discretionarytax on vesting | 3,526 | $8.94 | $32K | -4.9% | 2 tranches |
| Oct 17, 2025 | Adler EricChief Medical Officer · O | ▼ Sale | Non-discretionarytax on vesting | 3,382 | $8.94 | $30K | -4.4% | 2 tranches |
| Aug 18, 2025 | Otero Jose ManuelChief Technical Officer · O | ▼ Sale | Non-discretionarytax on vesting | 721 | $9.27 | $7K | -1.1% | late |
| Aug 18, 2025 | Otero Jose ManuelChief Technical Officer · O | ▼ Sale | Non-discretionarytax on vesting | 2,848 | $4.67 | $13K | -4.5% | — |
| Aug 18, 2025 | Robertson JennyChief Legal Officer · O | ▼ Sale | Non-discretionarytax on vesting | 542 | $4.67 | $3K | -0.9% | — |
| Aug 18, 2025 | Adler EricChief Medical Officer · O | ▼ Sale | Non-discretionarytax on vesting | 608 | $4.67 | $3K | -0.9% | — |
| Aug 18, 2025 | Townsend Richard NolanChief Executive Officer · O·D | ▼ Sale | Non-discretionarytax on vesting | 2,735 | $4.67 | $13K | -1.2% | — |
| Aug 18, 2025 | See Tai SandiChief Development Officer · O | ▼ Sale | Non-discretionarytax on vesting | 382 | $4.67 | $2K | -0.6% | — |
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Lexeo Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $LXEO feed.